These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 22133328)
1. Tetrabenazine: for chorea associated with Huntington's disease. Scott LJ CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D; Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099 [TBL] [Abstract][Full Text] [Related]
3. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease. Heo YA; Scott LJ Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203 [TBL] [Abstract][Full Text] [Related]
4. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Huntington Study Group Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934 [TBL] [Abstract][Full Text] [Related]
5. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Dean M; Sung VW Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277 [TBL] [Abstract][Full Text] [Related]
6. Tetrabenazine (Xenazine) for Huntington's chorea. Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140 [No Abstract] [Full Text] [Related]
7. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. Gamez J; Calopa M; Muñoz E; Ferré A; Huertas O; McAllister K; Reig N; Scart-Grès C; Insa R; Kulisevsky J Br J Clin Pharmacol; 2023 May; 89(5):1656-1664. PubMed ID: 36494329 [TBL] [Abstract][Full Text] [Related]
8. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. Frank S BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666 [TBL] [Abstract][Full Text] [Related]
9. Deutetrabenazine for the treatment of Huntington's chorea. Bashir H; Jankovic J Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061 [TBL] [Abstract][Full Text] [Related]
10. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Koch J; Shi WX; Dashtipour K Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050 [TBL] [Abstract][Full Text] [Related]
11. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Claassen DO; Philbin M; Carroll B Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641 [No Abstract] [Full Text] [Related]
12. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM; JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723 [TBL] [Abstract][Full Text] [Related]
13. Deutetrabenazine in the treatment of Huntington's disease. Richard A; Frank S Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137 [TBL] [Abstract][Full Text] [Related]
14. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. ; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342 [TBL] [Abstract][Full Text] [Related]
15. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. Frank S; Testa C; Edmondson MC; Goldstein J; Kayson E; Leavitt BR; Oakes D; O'Neill C; Vaughan C; Whaley J; Gross N; Gordon MF; Savola JM; CNS Drugs; 2022 Nov; 36(11):1207-1216. PubMed ID: 36242718 [TBL] [Abstract][Full Text] [Related]
20. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Chen JJ; Ondo WG; Dashtipour K; Swope DM Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]